Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4001 |
Name | ovarian carcinoma |
Definition | An ovarian cancer that has_material_basis_in epithelial tissue and is located_in the ovary. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600X PIK3CA H1047X | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus | ovarian carcinoma | predicted - sensitive | detail... |
TP53 I195* TP53 R248Q | ReACp53 | ovarian carcinoma | sensitive | detail... |
TP53 Y234C | ReACp53 | ovarian carcinoma | sensitive | detail... |
TP53 Y327L | ReACp53 | ovarian carcinoma | sensitive | detail... |
TP53 inact mut | ReACp53 | ovarian carcinoma | sensitive | detail... |
TP53 mutant | Adavosertib | ovarian carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00989651 | Phase I | Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin | Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01248962 | Phase II | Carboplatin | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01281514 | Phase I | Carboplatin + Everolimus + Pegylated liposomal doxorubicin | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT01504126 | Phase I | Propranolol | Beta-Blocker / Ovarian | Completed | USA | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | CAN | 1 |
NCT01669798 | Phase II | Nintedanib | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | Completed | USA | 0 |
NCT01849874 | Phase III | Binimetinib | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 9 |
NCT01936974 | Phase II | Bevacizumab + Cisplatin + Gemcitabine Bevacizumab + Gemcitabine + Oxaliplatin Bevacizumab + Carboplatin + Gemcitabine Bevacizumab + Gemcitabine | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Terminated | USA | 0 |
NCT01940172 | Phase I | Conatumumab Birinapant | Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer | Completed | USA | 0 |
NCT01974765 | Phase II | Enzalutamide | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | Completed | USA | 0 |
NCT02042430 | Phase I | Epacadostat | INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Terminated | USA | 0 |
NCT02098343 | Phase Ib/II | Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | Completed | USA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT02101775 | Phase II | Gemcitabine Adavosertib + Gemcitabine | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02101788 | Phase II | Topotecan Letrozole + Paclitaxel + Pegylated liposomal doxorubicin + Tamoxifen Trametinib | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Active, not recruiting | USA | GBR | 0 |
NCT02121990 | Phase I | Bevacizumab + Cisplatin + Olaparib + Paclitaxel | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
NCT02122185 | Phase II | Metformin Carboplatin + Docetaxel + Paclitaxel | Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Suspended | USA | 0 |
NCT02166905 | Phase Ib/II | Poly ICLC Rasdegafusp alfa Epacadostat | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Completed | USA | 0 |
NCT02270372 | Phase I | Varlilumab ONT-10 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | Completed | USA | 0 |
NCT02283658 | Phase II | Everolimus + Letrozole | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT02431559 | Phase Ib/II | Aldoxorubicin + Durvalumab + Motolimod | A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated | Completed | USA | 1 |
NCT02440425 | Phase II | Paclitaxel Pembrolizumab | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02459301 | Phase I | Monalizumab | Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin | Completed | CAN | 0 |
NCT02470585 | Phase III | Carboplatin Paclitaxel Veliparib | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | GBR | ESP | AUS | 7 |
NCT02485990 | Phase Ib/II | Olaparib Tremelimumab | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | Terminated | USA | 0 |
NCT02489006 | Phase II | Olaparib | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | Active, not recruiting | GBR | ESP | CAN | 1 |
NCT02520115 | Phase I | Dexamethasone Valproic acid | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | Completed | USA | 0 |
NCT02571725 | Phase Ib/II | Olaparib + Tremelimumab | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02608684 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | Completed | USA | 0 |
NCT02657928 | Phase II | Letrozole + Ribociclib | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | Completed | USA | 0 |
NCT02659241 | Phase I | Adavosertib | A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02661815 | Phase I | Paclitaxel + Ricolinostat Bevacizumab | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02665416 | Phase I | RO5520985 + Selicrelumab Bevacizumab + Selicrelumab | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors | Completed | USA | ITA | ESP | CAN | BEL | 2 |
NCT02759588 | Phase Ib/II | GL-ONC1 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02764333 | Phase II | Durvalumab + TPIV 200 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | Completed | USA | 0 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02953457 | Phase II | Durvalumab + Olaparib + Tremelimumab | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | Active, not recruiting | USA | 0 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT03017131 | Phase I | Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03029403 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Active, not recruiting | CAN | 0 |
NCT03220932 | Phase III | Bevacizumab Cisplatin | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer (HIPOVA-01) | Unknown status | FRA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03878849 | Phase II | E7449 | Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP (PREDICT 2X-121) | Recruiting | USA | GBR | 0 |
NCT03924245 | Phase Ib/II | Entinostat Entinostat + Olaparib | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | Terminated | USA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04274426 | Phase II | Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA) | Recruiting | DEU | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | ESP | CAN | BEL | 10 |
NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
NCT04861181 | FDA approved | Niraparib | NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK) | Recruiting | FRA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Active, not recruiting | USA | 0 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05636111 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | Not yet recruiting | USA | 0 |